Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate alzheimer disease

Clinical Neuropharmacology

Volumn 36, Issue 1, 2013, Pages 8-13

  Burstein, Aaron H ^a   Zhao, Qinying ^a   Ross, Joel ^b   Styren, Scot ^a   Landen, Jaren W ^a   Ma, Wendy W ^a   McCush, Fred ^a   Alvey, Christine ^a   Kupiec, James W ^a   Bednar, Martin M ^a  

^a PFIZER INC   (United States)

^b Memory Enhancement Center   (United States)

Author keywords

amyloid A; immunotherapy; monoclonal antibody; pharmacodynamics; pharmacokinetics

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PONEZUMAB;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COGNITION; DEPRESSION; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; EDEMA; ENCEPHALITIS; FATIGUE; FEMALE; GASTROENTERITIS; HAND FRACTURE; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; HYPESTHESIA; LETHARGY; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PYURIA; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VASOGENIC EDEMA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84872970450     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318279bcfa     Document Type: Article

References (16)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
2. Bateman R. The Dominantly Inherited Alzheimer Network interim results. Paper presented at: Annual Meeting of the Alzheimers Association International Conference; July 20, 2011; Paris, France.
3. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
4. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121-127.
5. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
6. Bednar MM. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease. IDrugs 2009;12:566-575.
7. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
8. Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:14657-14662.
9. Morgan D. Passive immunotherapies as an approach to disease modification in Alzheimer's disease. Satellite symposium, International Conference on Alzheimer's Disease; 2008; Chicago, IL.
10. Carty NC, Wilcock DM, Rosenthal A, et al. Intracranial administration of deglycosylated C-terminalYspecific anti-AA antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 2006;3:11.
11. Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated antiYamyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26: 5340-5346.
12. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against AA in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1;1-24.
13. Fredrickson J, Maruff P, Woodward M, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology 2010;34:65-75.
14. Salloway S, Sperling R, Gilman S, et al. Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-2070.
15. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73.
16. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION) and Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2). Available at: http://clinicaltrials.gov/ct2/results?term= solanezumab, accessed December 9, 2011.